Aspectos Atuais da Anemia na Doença Renal Crônica Actual Aspects of Anemia in Chronic Kidney Disease

Anemia is a complication of chronic kidney disease. It has several causes. Relative erythropoietin deficiency and iron shortage are the main causes. Anemia induces cutaneous pallor, weakness, indisposition, lack of attention, impairment of quality of life and higher mortality in pat ients with chronic kidney disease. This review discusses the importance of inflammation as an etiologic agent of anemia in chronic kidney disease and the possible role of anemia in chronic

[1]  K. Siamopoulos,et al.  Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. , 2004, Kidney international.

[2]  A. Schwartz,et al.  Anemia of chronic kidney disease: A combined effect of marginal iron stores and erythropoietin deficiency , 2004 .

[3]  M. Tapolyai,et al.  r.hu-Erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline , 2003, BMC nephrology.

[4]  B. Brenner,et al.  The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. , 2003, Kidney international.

[5]  V. Jorgetti,et al.  IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. , 2003, Kidney international.

[6]  W. Jelkmann,et al.  Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA‐2 and NF‐κB , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  W. Hörl,et al.  Contribution of anaemia to progression of renal disease: a debate. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Jungers,et al.  Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  E. Ku.  Pathophysiology of renal anemia. , 2000 .

[11]  K. Eckardt.  Pathophysiology of renal anemia. , 2000, Clinical nephrology.

[12]  S. Srinivasula,et al.  Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1 , 1999, Nature.

[13]  I. Macdougall,et al.  Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. , 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[14]  R. Fudin,et al.  Correction of Uremic Iron Deficiency Anemia in Hemodialyzed Patients: A Prospective Study , 1998, Nephron.

[15]  A R Nissenson,et al.  The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.